Paclitaxel/5-FU Promising in Metastatic Breast Cancer
ROME, Italy-The combination of paclitaxel (Taxol), fluorouracil (5-FU), and leucovorin, with G-CSF support, in pretreated patients with advanced breast cancer had a good toxicity profile and an encouraging response rate in a study from the Regina Elena Cancer Institute, Rome.
ROME, ItalyThe combination of paclitaxel (Taxol), fluorouracil (5-FU),and leucovorin, with G-CSF support, in pretreated patients with advancedbreast cancer had a good toxicity profile and an encouraging response ratein a study from the Regina Elena Cancer Institute, Rome.
In the poster presentation, Dr. E. Terzoli described 16 heavily pretreatedadvanced breast cancer patients who received paclitaxel, 135 to 175 mg/m²onday 1 and fluorouracil, 350 to 375 mg/m², plus leucovorin, 10 to 100mg/m², on days 1 to 3. The cycle was repeated every three weeks withG-CSF added to prevent neutropenia.
The combination therapy was delivered as first-line metastatic treatmentin three patients, second-line in five patients, and third-line or higherin eight patients. All patients had received previous anthracyclines, andeight had taken hormones.
Five of 10 evaluable patients had a partial response, and in four ofthese patients, the treatment represented third-line chemotherapy. Overall,the combination was well tolerated.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
